A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis.
Not yet recruiting
Phase of Trial: Phase 0
Latest Information Update: 03 Oct 2018
At a glance
- Drugs Saracatinib (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms SCRIPT
- 24 Sep 2018 Planned initiation date changed from 1 Sep 2018 to 1 Dec 2018.
- 12 Sep 2018 New trial record